Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
NCT00002836
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which treatment regi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/05/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
NCT02560038
Terminated
This trial is for people with bladder cancer that has spread. The purpose of this research study is to see if the chemotherapy combination of gemcitabine and cisplatin plus paclitaxel is safe and effective treatment for bladder cancer. Paclitaxel, gemcitabine and cisplatin have all been approved by the United States Food and Drug Administration (FDA). Gemcitabine and cisplatin is a standard treatment for bladder cancer. There have been studies that show that paclitaxel and cisplatin have antitu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2018
Locations: UTHealth Memorial Hermann Cancer Center, Houston, Texas
Conditions: Urinary Bladder Neoplasms
Register for Updates
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
NCT00215501
Completed
The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with unresectable, advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2018
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Solid Tumor
Register for Updates
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00016367
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study effectiveness of combining cisplatin, gemcitabine, and trastuzumab in treating patients who have stage... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2018
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCT00926640
Completed
BACKGROUND: * The histone deacetylase (HDAC) inhibitors are a novel class of anticancer agent. These agents lead to the increased acetylation of both histone and non-histone proteins, which leads to rapid cell death in many tumor models. It is thought that the cell death observed with this class of agents may be mediated, in part, through the selective acetylation of histone proteins resulting in increased expression of specific genes. * For solid tumors in general, cell death in preclinical mo... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/18/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms
Register for Updates
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
NCT02254681
Terminated
The overall goal of this study is to determine the safety and efficacy of combination treatment of low-dose fractionated radiation therapy with gemcitabine-cisplatin chemotherapy for locally advanced mass forming intra-hepatic cholangiocarcinoma.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/02/2018
Locations: Virginia Piper Cancer Institute, Minneapolis, Minnesota
Conditions: Intrahepatic Cholangiocarcinoma
Register for Updates
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
NCT00454779
Completed
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically con... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/20/2018
Locations: Research Site, Tucson, Arizona +113 locations
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Register for Updates
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
NCT01752023
Terminated
Response rates. Changes in tumor blood flow.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/18/2018
Locations: Bayview Medical Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Non-small Cell Lung Cancer Metastatic
Register for Updates
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
NCT00064077
Completed
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2018
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Register for Updates
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
NCT02375880
Completed
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
09/06/2018
Locations: University of Southern California, Los Angeles, California +8 locations
Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
Register for Updates
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00002461
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients wit... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
08/15/2018
Locations: Albert Einstein Comprehensive Cancer Center, Bronx, New York
Conditions: Lymphoma
Register for Updates
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01218048
Completed
There are currently no useful tests to identify patients who will respond to cetuximab therapy, notably because EGFR levels do not correlate with the clinical responses observed. Thus, the investigators are investigating the role of cellular immunity and immune escape mechanisms to explain the differential clinical response to cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2018
Locations: UPCI - Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates